CluePoints Chief Scientific Officer and Pfizer’s Global RBM Program Lead to Speak at #CQOF2021
Join us at #CQOF2021! As well as hosting a booth at the Clinical Quality Oversight Forum where visitors will be able to learn about our…
Read More
Will ICH E6 (R3) Unleash the Potential of Risk-Based Trials?
Researchers have been slow to fully adopt innovations designed to overcome the challenges to modern day clinical research, in no small part due to a…
Read More
CluePoints Partners with ZS to Provide Best-in-Class RBQM Expertise and Technology, Increasing Clinical Trial Efficiency and Improving Patient Outcomes
August 25, 2021: CluePoints, the premier provider of Risk-Based Quality Management software for clinical trials, has partnered with ZS, a global professional services firm with technology and…
Read More
CluePoints’ Launch Post-COVID Trial Assurance Solution
King of Prussia, PA – June 29, 2021: CluePoints, the premier provider of Risk-Based Quality Management Solutions for clinical trials, has launched a new Post-COVID Trial Assurance…
Read More
Software Engineering Skills for a Big Societal Impact
Challenge, opportunity, fun, and the chance to make a difference – CluePoints has everything a talented software engineer is looking for. That’s according to Philippe…
Read More
Introducing CluePoints’ Post-COVID Trial Assurance Solution
For well over a year now, the clinical research community has been hard at work to maintain progress in developing new treatments and therapies to…
Read More
Using Risk-Based Monitoring to Focus on What Matters
Rich Davies, VP Solutions Expert at CluePoints, and Tanya du Plessis, VP Data Solutions and Strategies at Bioforum, explain how to apply the principles of…
Read More
Revealing the Bigger Picture Through Metadata & Building RBQM Standards of the Future
Risk-Based Monitoring is the future of clinical trials – but despite significant advances in recent years, some of the practicalities of implementation need to be…
Read More
Events
Find out where we’re headed next.
Featured Whitepaper
ICH E6 (R2)
Summary
Paper
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
Featured Webinar
ICH E6 (R2)
Webinar
Series
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.
We're Kind of a Big Deal.
3,400
Platform Users
700
Studies De-Risked
64,000
Issues Detected